Development and application of a graded evidence framework for the association between gut microbiota-derived metabolites and diabetic retinopathy

Objective The gut–retina axis hypothesis suggests that microbial metabolites contribute to diabetic retinopathy (DR); however, the existing evidence remains heterogeneous, and no systematic grading framework has been established to date. We developed a four-tier (I–IV) evidence-grading framework specifically tailored to the gut–retina axis. Methods The framework was adapted from established methodologies, including the Systematic Review and Integrated Assessment (SYRINA), the Evidence Integration Framework (EIF), and the International Agency for Research on Cancer (IARC) Preamble, with prespecified criteria for assessing metabolite–DR associations. Systematic searches in PubMed, Scopus, Embase, and Web of Science (2001–2026) identified 29 original studies. Two reviewers independently graded the evidence, with substantial inter-rater agreement (Cohen’s κ = 0.89). Results None of the 17 metabolites met Level I criteria. Valine attained Level II-B, supported by Mendelian randomization (MR) evidence for a composite DR endpoint (OR = 1.51, 95% CI: 1.31–1.76; statistically significant after Bonferroni correction (P < 3.78 × 10 -5 ); exact P not reported). Level III (suggestive) comprised three metabolites: SCFA deficiency, TMAO, and LPS; TUDCA was classified as III-conflicting. Level IV (exploratory) included 12 metabolites: ImP, colibactin, virome, fungal microbiota, PCS, H 2 S, UDCA, BCAAs, IPA, PAGln, IS, and MGO. Conclusion MR studies are needed for most substances to establish causal evidence. The evidence map provides a proof-of-concept demonstration (version 1.0). Grades are hypothesis-generating; external validation is required before clinical use. Systematic review registration https://doi.org/10.17605/OSF.IO/D48Z2 , identifier 10.17605/OSF.IO/D48Z2

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-13
DOI
https://doi.org/10.3389/fendo.2026.1974709
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development and application of a graded evidence framework for the association between gut microbiota-derived metabolites and diabetic retinopathy

朱德军, Jiyun Wang, Zhaogang Lu, Rui Wang et al.
2 links
Frontiers in Endocrinology
Gut microbiota and health
article

Development and application of a graded evidence framework for the association between gut microbiota-derived metabolites and diabetic retinopathy

朱德军, Jiyun Wang, Zhaogang Lu, Rui Wang, Wenli Wu, Dan Wang, Jing Jing
article en

Abstract

Objective The gut–retina axis hypothesis suggests that microbial metabolites contribute to diabetic retinopathy (DR); however, the existing evidence remains heterogeneous, and no systematic grading framework has been established to date. We developed a four-tier (I–IV) evidence-grading framework specifically tailored to the gut–retina axis. Methods The framework was adapted from established methodologies, including the Systematic Review and Integrated Assessment (SYRINA), the Evidence Integration Framework (EIF), and the International Agency for Research on Cancer (IARC) Preamble, with prespecified criteria for assessing metabolite–DR associations. Systematic searches in PubMed, Scopus, Embase, and Web of Science (2001–2026) identified 29 original studies. Two reviewers independently graded the evidence, with substantial inter-rater agreement (Cohen’s κ = 0.89). Results None of the 17 metabolites met Level I criteria. Valine attained Level II-B, supported by Mendelian randomization (MR) evidence for a composite DR endpoint (OR = 1.51, 95% CI: 1.31–1.76; statistically significant after Bonferroni correction (P < 3.78 × 10 -5 ); exact P not reported). Level III (suggestive) comprised three metabolites: SCFA deficiency, TMAO, and LPS; TUDCA was classified as III-conflicting. Level IV (exploratory) included 12 metabolites: ImP, colibactin, virome, fungal microbiota, PCS, H 2 S, UDCA, BCAAs, IPA, PAGln, IS, and MGO. Conclusion MR studies are needed for most substances to establish causal evidence. The evidence map provides a proof-of-concept demonstration (version 1.0). Grades are hypothesis-generating; external validation is required before clinical use. Systematic review registration https://doi.org/10.17605/OSF.IO/D48Z2 , identifier 10.17605/OSF.IO/D48Z2

Frontiers in EndocrinologyVol. 17
Integrated Chinese Medicine (China) (HK), Ningxia Hui Autonomous Region Peoples Hospital (CN), Ningxia Medical University (CN), The Fourth People's Hospital of Ningxia Hui Autonomous Region (CN)
Natural Science Foundation of Ningxia Province
Good health and well-being
Gut microbiota and health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon